Pictet Asset Management Holding SA Has $15.16 Million Stock Holdings in Biohaven Ltd. (NYSE:BHVN)

Pictet Asset Management Holding SA lifted its holdings in shares of Biohaven Ltd. (NYSE:BHVN - Free Report) by 32.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 405,848 shares of the company's stock after purchasing an additional 98,779 shares during the quarter. Pictet Asset Management Holding SA owned approximately 0.40% of Biohaven worth $15,158,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Point72 Asset Management L.P. boosted its holdings in Biohaven by 745.9% in the third quarter. Point72 Asset Management L.P. now owns 1,500,284 shares of the company's stock worth $74,969,000 after purchasing an additional 1,322,922 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Biohaven by 144.5% during the 4th quarter. JPMorgan Chase & Co. now owns 1,979,169 shares of the company's stock worth $73,922,000 after acquiring an additional 1,169,721 shares in the last quarter. Norges Bank acquired a new position in shares of Biohaven during the 4th quarter valued at about $33,711,000. Vanguard Group Inc. raised its stake in shares of Biohaven by 8.1% in the 4th quarter. Vanguard Group Inc. now owns 8,414,120 shares of the company's stock valued at $314,267,000 after acquiring an additional 628,211 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Biohaven by 563.4% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 508,622 shares of the company's stock worth $25,416,000 after purchasing an additional 431,954 shares during the last quarter. Institutional investors own 88.78% of the company's stock.

Remove Ads

Analysts Set New Price Targets

Several equities analysts have commented on BHVN shares. Cantor Fitzgerald reiterated an "overweight" rating on shares of Biohaven in a report on Tuesday, December 17th. Royal Bank of Canada reiterated an "outperform" rating and issued a $61.00 target price on shares of Biohaven in a research note on Tuesday, March 4th. HC Wainwright reissued a "buy" rating and set a $54.00 target price on shares of Biohaven in a research report on Tuesday, March 4th. JPMorgan Chase & Co. cut their price objective on Biohaven from $72.00 to $68.00 and set an "overweight" rating for the company in a research report on Wednesday, March 5th. Finally, Deutsche Bank Aktiengesellschaft set a $60.00 target price on Biohaven and gave the company a "buy" rating in a report on Thursday, March 20th. Fourteen analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $62.77.

Insider Transactions at Biohaven

In other news, Director John W. Childs bought 32,700 shares of the stock in a transaction dated Tuesday, March 4th. The shares were acquired at an average price of $30.47 per share, with a total value of $996,369.00. Following the acquisition, the director now owns 2,320,571 shares in the company, valued at $70,707,798.37. This trade represents a 1.43 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 16.00% of the stock is currently owned by insiders.

Biohaven Stock Down 9.8 %

Biohaven stock traded down $2.01 on Friday, hitting $18.54. The company's stock had a trading volume of 2,580,699 shares, compared to its average volume of 1,101,033. The company has a fifty day moving average price of $33.40 and a 200-day moving average price of $40.82. The firm has a market cap of $1.89 billion, a P/E ratio of -1.98 and a beta of 1.33. Biohaven Ltd. has a one year low of $17.93 and a one year high of $55.70.

Biohaven (NYSE:BHVN - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($1.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.56) by ($0.29). Analysts anticipate that Biohaven Ltd. will post -8.9 EPS for the current year.

Biohaven Profile

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.